Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma

Marcie Tomblyn, Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The PARMA trial clarified the role of hematopoietic stem cell transplant in patients with non-Hodgkin's lymphoma in chemotherapy-sensitive relapse. With the goal of improving overall response and survival rates, hematopoietic stem cell transplant has been incorporated into the front-line treatment plan in some studies. While multiple clinical trials have been designed to address this issue, they have varied in their treatment regimens, patient populations and outcomes. This review will summarize and analyze the data obtained so far and provide practitioners with recommendations for the application of high-dose chemotherapy and hematopoietic stem cell transplant as part of the initial treatment of patients with both indolent and aggressive non-Hodgkin's lymphoma. Based upon the current literature, hematopoietic stem cell transplant cannot be recommended as first-line therapy in patients with non-Hodgkin's lymphoma outside the setting of a clinical trial.

Original languageEnglish (US)
Pages (from-to)281-294
Number of pages14
JournalExpert review of anticancer therapy
Volume3
Issue number3
DOIs
StatePublished - Jun 2003

Keywords

  • Hematopoietic stem cell transplant
  • Non-Hodgkins lymphoma
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this